Bajaj Healthcare outlines growth strategy, financial performance

Bajaj Healthcare Limited announced an investor presentation on December 8, 2025, ahead of an upcoming analyst and institutional investor meeting. The presentation details the company's "Bajaj Oncocare" division, which includes plans for an oncology API plant by 2027 and a dedicated section of the Nashik plant for oncology oral dosage formulation. Additionally, Bajaj Healthcare is constructing a state-of-the-art peptide manufacturing plant, scheduled for commercialization by March 2026, with an installed capacity of approximately 250 kg per annum. The R&D team has already developed six peptide molecules, including GLP-1 (Semaglutide).

For the half-year ended September 2025 (HYE Sept 2025), Bajaj Healthcare reported a total income of ₹299.28 Cr and an EBITDA of ₹53.99 Cr. Profit for the period stood at ₹22.94 Cr. The company's revenue mix for HYE Sept 2025 shows domestic sales at 36% and exports at 64%. API products contributed 16% of revenue, with formulations accounting for 84%. The net worth as of Sept 2025 was ₹486.39 Cr.

Bajaj Healthcare also highlighted its global presence, with products in over 60 countries. The company secured two contracts from the Government of India for processing opium gum and poppy straw at its alkaloid extraction plant in Vadodara, Gujarat, with capacities of 250 MTPA and 2500 MTPA, respectively.